ROF, which was used as an antidepressant in the 1980s, is the first selector PDE4 inhibitor approved for human usage in 2010, with the primary indication being chronic obstructive pulmonary disease (COPD) (5, 6). The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.